Investor's Business Daily on MSN14m
Neurogene — Down 36% — Extends Losses After Side Effect Derails Its Rett Syndrome Drug
Neurogene stock collapsed, again, on Monday after the company scrapped the high dose of its experimental Rett syndrome ...